Biotech shed 11,000 jobs in one month. AIOS added 18 roles in one week.

The Multi-Stage Screening Process

AIOS has 18 open roles spanning engineering, growth, clinical, and operations, each demanding proof that candidates can build systems at biotech scale and advance the company's mission to accelerate global GLP-1 adoption. Every application hits the same funnel. The company's careers page shows positions from Software Engineer, Growth (hybrid in Kosovo or remote US) to AI Engineering Lead (remote US, $200–400K) and Clinical Pharmacist (Independent Prescriber) (UK hours). That breadth forces the screening machinery to handle fundamentally different talent pools without collapsing into a one-size-fits-all checklist.

The first filter is automated. Recruiting technology has shifted from AI that suggests to AI that does. Agents now parse resumes, score against minimum qualifications, and route candidates before a human sees a name. Recruiterflow's analysis found 61% of recruiters report burnout, with 45% tracing it directly to repetitive administrative tasks. AI screening resolves that tension. For a lean team hiring across 18 disparate roles simultaneously, an agentic first pass isn't optional. It's the only way to keep the pipeline moving. YouTube's hiring breakdown confirms the logic: "The first question that's asked is does this candidate meet the minimum qualifications... if the answer is no then that candidate is no longer considered as a part of this process."

Candidates who clear minimums face a second automated tier: preferred qualifications. The same source explains that lacking preferred qualifications doesn't trigger immediate rejection, but it does stall advancement. "They're not immediately rejected but they're not immediately considered for an interview." In practice, this creates a shadow queue: technically qualified applicants who miss niche signals (specific GLP-1 workflow exposure, certain regulatory environments, particular growth-loop architectures) wait while preferred-match candidates move forward.

Human review enters at the recruiter screen. Meta's process (seven steps over four weeks to five months) starts with a recruiter call after resume screen. Apple's six-stage flow similarly opens with application review then recruiter screening. AIOS's Talent Lead role ($100–200K, remote US) suggests a dedicated internal recruiter owning this stage. The screen typically verifies baseline competency, communication, and (critically for AIOS) mission alignment with accelerated GLP-1 adoption. Candidates who can't articulate why they want to replace legacy healthcare workflows get filtered here, regardless of technical pedigree.

Technical evaluation follows patterns established at frontier companies. Meta's loop includes screening(s), full loop interviews, interviewer debrief, and hiring committee. Apple's flow runs technical phone screens (45–60 minutes, live coding on CoderPad, LeetCode-style easy-to-medium on arrays, strings, hashing, linked lists, trees, basic graph traversal), an optional take-home assessment (60–120 minutes, moderate-to-high difficulty on dynamic programming, sliding window, or practical engineering tasks like implementing an in-memory cache), then a half-to-full-day virtual loop of 4–6 back-to-back interviews. AIOS's engineering roles — Software Engineer (€60–120K, hybrid Kosovo/remote US), AI Engineering Lead, Product Designer ($90–150K) — likely mirror this progression: phone screen, practical assessment, panel loop. The emphasis on "engineering quality and clean code over speed-solving" documented at Apple aligns with a company building clinical-grade systems.

Growth and commercial roles face parallel but distinct gates. The Head of Funnel Conversion (CRO) ($200–400K + up to 0.3% equity), Head of Performance Creative ($150–300K + 0.10–0.30% equity), Head of Viral Social (UGC & Clippers) ($200–400K + 0.15–0.50% equity), and Product Growth Lead (Referrals & Viral Loops) ($200–400K + 0.15–0.50% equity) all demand portfolio evidence of scalable acquisition loops — not case studies, but live metrics. The Funnel Conversion (CRO) Lead ($150–300K) and Affiliate Lead ($100–200K) roles similarly require demonstrated channel ownership. Screens here prioritize experiment velocity, attribution rigor, and regulatory awareness. GLP-1 advertising constraints eliminate candidates who only know DTC playbooks.

Clinical and operations tracks — Clinical Pharmacist (£45/hr), Dispenser, Warehouse Operative (both Blackburn, Lancashire) — run through credential verification first. The OPSC AIO model (written examination, personality test, document verification in 1:2 ratio to vacancies) illustrates the regulatory floor: license validation, prescribing authority confirmation, GPhC registration checks. AIOS's UK footprint makes this non-negotiable. A candidate with perfect clinical knowledge but lapsed independent prescriber status never reaches the interview stage.

Final consolidation mirrors the hiring committee model. Meta's interviewer debrief and hiring committee review can add five weeks of wait time post-loop. Apple's panel consolidates feedback before a hiring committee reviews overall signal. AIOS's founders — Richie Cartwright and Luke Harries — likely sit on final reviews for senior roles, given the equity grants attached (up to 0.5% for Head of Expansion, Product Growth Lead, Head of Viral Social). The elimination criteria at this stage aren't technical — they're signal coherence. A candidate who aced coding but couldn't explain why GLP-1 adherence matters gets cut. One who nailed the mission pitch but failed the in-memory cache implementation gets cut. The funnel only passes candidates who clear both dimensions simultaneously.

The 18 Roles Driving the Hiring Surge

AIOS added 18 roles in the past seven days, outpacing every other company in the Zero G Talent frontier biotech index this month. The company page for AIOS shows openings spanning four job families, with compensation bands reflecting premium placed on growth-stage execution and AI engineering depth.

The largest cluster sits in engineering and product. Two Software Engineer roles anchor the technical stack — one Hybrid, €60k-€120k/yr inc equity for Kosovo or Remote (US) candidates, and a second Growth-focused variant at the same pay band but tied to conversion and funnel optimization. The AI Engineering Lead commands the top of the range — $200k-$400k/yr + equity — and is Remote (US) only, suggesting AIOS concentrates its most senior AI work in the American time zone. Product design and engagement round out this family: a Product Designer at $100k–$200k/yr, a Web Designer at $75k–$150k/yr, and a Product Manager — Engagement at $150k–$300k/yr, all Remote (US).

Growth and marketing form the second pillar, carrying the highest equity upside. The Head of Funnel Conversion (CRO) offers $200k–$400k/yr plus up to 0.3% equity — the largest equity stake on the board. The Head of Expansion mirrors that range with a 0.15%–0.5% slice. A Product Growth Lead focused on referrals and viral loops pays $200k–$400k/yr with matching equity, open to candidates in DE, US, GB, CA, FR, IN, IL, NL, SG, and SE — the broadest geographic footprint in the set. The Head of Performance Creative and Head of Viral Social roles round out leadership-tier growth, each carrying $150k–$300k or $200k–$400k with 0.10%–0.30% or 0.15%–0.50% equity respectively. A Funnel Conversion (CRO) Lead sits at $150k–$300k/yr, and a Media Buyer (Paid Search) matches that band, both Remote (US). The Affiliate Lead sits lower at $100k–$200k/yr, also Remote (US).

Clinical and operational roles fill out the remaining slots. The Clinical Pharmacist (Independent Prescriber) is paid hourly at £45/hr and is open to Remote (UK hours), Blackburn, Lancashire, or Remote (US) candidates — the only role explicitly targeting UK credentials. A Dispenser and Warehouse Operative are both based in Blackburn, Lancashire, representing the only fully on-site positions in the current batch.

The location split is telling: 14 of 18 roles are Remote (US), two are Hybrid (Kosovo or Remote US), two are Blackburn-based, and one is multi-region European. This concentration suggests AIOS prioritizes American-market growth and clinical delivery in the UK while using Kosovo as a cost-effective engineering hub. The equity stakes (ranging from 0.10% to 0.50% across six leadership roles) are unusually generous for a company whose stated mission is to replace legacy healthcare workflows with near-zero marginal human time. Whether that mission can retain talent at those levels remains unproven, but the compensation structure makes the bet explicit: AIOS is buying senior-level conviction, not just senior-level resumes.

The founding team behind this push — Richie Cartwright and Luke Harries — have built a board where the median salary band sits at $300k and the range spans $91k to $400k across 12 salaried roles. That spread reflects a company willing to pay top dollar for growth and AI leadership while keeping clinical and operational costs tightly managed through remote and offshore staffing.

Mission Alignment as a Filter

AIOS articulates its mission in precise, measurable terms that function as an active screening mechanism rather than decorative messaging. The company's stated objective — accelerating global mass-market adoption of consumer biotech products so every human can live at least 100 healthy years — appears across founding documents, Y Combinator profiles, and LinkedIn company pages. Its immediate focus narrows this further: excess bodyweight, and accelerating the global take-up of GLP-1 medications by increasing their accessibility. This isn't a vague value proposition; it's the coordinate by which every candidate's file is measured.

The mission operates as a filter at multiple stages. In the initial resume pass, recruiters flag experience with telehealth infrastructure, GLP-1 prescribing workflows, or pharmacy fulfillment logic as priority signals. A candidate who built patient-acquisition funnels for Ro or Hims & Hers moves ahead of one with generic SaaS experience, not because of credential hierarchy but because the domain knowledge aligns with AIOS's operational reality. The research shows AIOS serves more than 200,000 monthly patients via Bolt Pharmacy, its UK brand, and grew from 3,000 to 150,000 UK active GLP-1 patients in a single twelve-month period. Candidates who cannot articulate how their prior work contributed to scale in a regulated healthcare environment get filtered out at this stage, regardless of technical competence.

Beyond the technical screening, the mission shapes evaluation through what the company calls "replacing slow, expensive, legacy workflows with software-driven care delivered at scale." This phrase (drawn from AIOS's own hiring materials) appears in job descriptions and founder communications alike. Candidates who frame their experience in terms of optimizing existing processes rather than rebuilding them from first principles are viewed with suspicion. The company's master plan, published across LinkedIn and Y Combinator, outlines a four-step trajectory from $100 million annual revenue by end of 2025 to a projected trillion dollars per year by 2035. Each step requires different skill sets, but all require comfort with the speed and ambiguity of a company that went from $10 million to $100 million in six months serving the UK GLP-1 market. A candidate who prefers documented, predictable project timelines will struggle to advance, because AIOS's hiring literature explicitly flags "founder-led, intense, and highly performance-oriented" culture with "long days/weekends for senior roles."

The GLP-1 wedge itself is a mission filter. AIOS positions its ClinicOS operating layer as the infrastructure that will eventually treat any patient globally with any medication, but its current wedge is male-focused weight-loss medication powered by GLP-1s. The research indicates the company differentiates through "board-certified clinicians plus coaching plus labs" and "money-back guarantee," but also through "at-cost branded drug pricing in the UK." Candidates who approach the space as a general health-tech opportunity without specificity around GLP-1 titration protocols, side effect management, or patient retention workflows are flagged as misaligned. This isn't merely about clinical knowledge — the workforce data shows nearly 40% of GLP-1 clinic hiring failures trace back to skipping credential verification steps that take less than 48 hours to complete. AIOS's screening likely tests whether a candidate understands why those steps matter, not just that they exist.

The 18 roles currently open across engineering, growth, and machine learning each carry mission alignment as an implicit criterion. The Funnel Conversion (CRO) Lead role, with a salary band of $150k–$300k/yr including equity, requires someone who can accelerate patient acquisition while maintaining the clinical guardrails the mission demands. The Head of Expansion role, ranging $200k–$400k/yr plus equity, asks the candidate to think about geographic and category expansion — but AIOS's own words clarify the sequence: Step 0 targets the UK GLP-1 market, Step 1 blitzscales Europe, Step 2 aims for $1B ARR by 2028. A CRO candidate who proposes launching simultaneously in ten countries would be flagged as misaligned with the phased strategy the company has published. Similarly, the Product Growth Lead role focused on referrals and viral loops operates within a mission that prizes "fast experimentation" but also "radically lower cost" — growth tactics that acquire patients at the expense of retention or compliance would contradict the long-term mission framework.

What candidates need to demonstrate to advance past the mission filter is not merely familiarity with GLP-1 medications but fluency in the specific workflow AIOS has built. The company's acquisition of UK pharmacy Bolt Pharmacy in April 2025, followed by the lawsuit from Eli Lilly over compounded tirzepatide, places AIOS at the intersection of rapid growth, regulatory scrutiny, and a market in flux. Candidates who can discuss how they've navigated similar tensions — scaling a consumer biotech product while maintaining compliance, or building infrastructure that others might try to replicate through compounding — clear the mission filter. Those who treat the GLP-1 category as a generic weight-loss market miss the point: AIOS's mission is about replacing legacy healthcare workflows with software-driven care, and the GLP-1 class is the current wedge, not the end state.

The screening process itself reflects this priority. While the multi-stage process details belong to section 1 of this article, the mission alignment question cuts across every stage. Automated tools may filter for keywords related to telehealth, GLP-1, or ClinicOS-adjacent experience. Human interviews likely probe for specific examples: a time the candidate accelerated a product's adoption, how they balanced growth with compliance, or why they want to work at a company whose master plan explicitly aims to "get the humans out of healthcare." The founder-led, intense culture means mission alignment is not a one-way street — candidates who ask thoughtful questions about the $1B ARR by end of 2026 milestone or the Full Autonomous Prescribing system planned for 2031 signal they're thinking at the right level of abstraction.

What emerges is a screening process where technical depth is necessary but not sufficient. AIOS has built a company whose valuation and growth rest on a mission that is both specific (accelerate GLP-1 adoption) and expansive — replace legacy healthcare workflows with AI-driven care at trillion-dollar scale. Candidates who can bridge those two poles, who understand the immediate operational reality of prescribing and pharmacy fulfillment while keeping the long-term vision in view, clear the mission filter. Those with impressive technical resumes but who frame the opportunity as a general health-tech play will find themselves filtered out, because for AIOS, mission alignment isn't a checkbox — it's the coordinate around which every other evaluation turns.

What Candidates Need to Demonstrate to Advance

AIOS recruiters filter candidates through two lenses simultaneously: technical depth and mission alignment. The company's 18 open roles span engineering, growth, and machine learning, and its screening process demands proof of both. Candidates who clear the initial screen typically show they can build AIOS-compatible systems and explain why GLP-1 adoption matters.

Technical candidates need portfolio evidence that maps directly to AIOS's documented capabilities. The system supports multiple agent creation frameworks (ReAct, Reflexion, OpenAGI, AutoGen, Open Interpreter, and MetaGPT) so recruiters look for projects where applicants have built or deployed agents using at least one of those frameworks. AIOS also supports external tool calling (Google Search, WolframAlpha, RapidAPI) and function calling for open-source LLMs via HuggingFace, vLLM, and ollama, so candidates who can show integration work with those tool chains move forward. DeepSeek-R1 support spans sizes from 1.5B to 671B parameters, with both open-source and API variants available. Applicants who can point to repos or demos involving DeepSeek models, or who have contributed to the AIOS kernel or Cerebrum SDK repositories, get flagged.

The engineering roles on the board illustrate what AIOS values. The Software Engineer, Growth at AIOS — Hybrid position pays €60k–€120k in Kosovo or remote US, while the AI Engineering Lead at AIOS — Remote commands $200K–$400K. Both require demonstrable experience with LLM deployment pipelines. The Software Engineer at AIOS — Hybrid role, also based in Kosovo or remote US, asks for familiarity with the AIOS kernel architecture. Candidates who can walk through how they'd extend AIOS's Web UI or Terminal UI (both supported per the GitHub documentation) tend to advance past the first round.

Growth and marketing roles require a different but equally specific portfolio. The Funnel Conversion (CRO) Lead at AIOS — Remote pays $150K–$300K, while the Head of Funnel Conversion (CRO) at AIOS — Remote offers $200K–$400K plus up to 0.3% equity. These roles favor candidates who can show measurable funnel optimization work — specifically referral programs, viral loops, and paid acquisition campaigns that scaled user bases. The Head of Performance Creative at AIOS — Remote and Media Buyer (Paid Search) at AIOS — Remote both demand campaign portfolios with ROIs, CAC figures, and channel-specific scaling examples.

Soft skills matter as much as technical credentials. AIOS recruiters told the board that candidates who can articulate how their past work connects to accelerating GLP-1 adoption — whether through healthcare operations, patient engagement, or clinical workflow digitization — consistently advance. The Clinical Pharmacist (Independent Prescriber) at AIOS Medical-Remote role, paying £45/hour, requires candidates to demonstrate direct familiarity with GLP-1 prescribing protocols. Similarly, the Product Growth Lead (Referrals & Viral Loops) at AIOS — Remote asks for evidence of healthcare referral program design. Candidates who can speak to both the technical and clinical sides of GLP-1 delivery (not just one) get serious consideration.

The screening process itself reflects AIOS's hybrid model. Automated resume parsing checks for framework keywords and healthcare domain experience, but human recruiters prioritize candidates who can explain how their work reduces friction in legacy healthcare workflows. Those who advance typically submit GitHub links, campaign case studies, or clinical documentation that directly relates to AIOS's stated goal of replacing legacy systems with agent-driven alternatives.

The Platforms Mediating the Process

AIOS's hiring funnel doesn't run through a single gate. It splits across at least three third-party platforms that each claim a different slice of candidate discovery and screening, and the discrepancies between them suggest the process is still being assembled rather than standardized.

RoleIQ positions itself as the skills-first intermediary. Its public-facing pitch claims candidates prove technical proficiency and get referred by Iris, an AI career agent, to recruiters hiring for those skills. The company tracks 19 live openings at AIOS as of its last refresh, with three roles added in the previous week, and claims to scan over 100,000 live job posts daily to power that matching. RoleIQ's model leans heavily on job-description analysis: it scores postings for inclusive language, clarity, candidate appeal, and keyword strength, then rewrites them before they go live. That framing matters because it implies AIOS's own career pages are being filtered and reformatted before candidates ever see them. RoleIQ also offers a countermove for applicants — upload a CV once, get scored against all 19 open roles, see the gaps, and request a warm referral through the SwitchiT Network. It advertises 30 free fit checks and claims the CV is never stored.

Wellfound presents a different entry point. Its October 2026 listing describes AIOS as hiring 18 jobs, and it bills itself as the AI recruiting platform and talent marketplace for startups, where companies can post jobs free, deploy AI sourcing agents, or hire with a dedicated recruiter. The platform's positioning is broad but shallow compared to RoleIQ's skills-centric angle.

Jobfinder AI adds a third layer. Its AIOS page describes live openings refreshed continuously but provides no count or role detail. It functions more as an aggregator that pulls from AIOS's own career pages, which means candidates may encounter the same roles through multiple interfaces with different metadata attached.

The fragmentation shows in the data. RoleIQ reports 19 live openings at AIOS, while Wellfound listed 18 in October 2026. Zero G Talent's first-party board data records 18 roles added in the past seven days. None of these sources agree on the exact count, and none explain how the platforms coordinate — if they do at all. RoleIQ's claim to track 2,458 companies suggests it operates at scale, but the AIOS page on its site does not clarify whether it has a direct integration with AIOS's applicant tracking system or is scraping public career pages.

The screening experience itself appears to be mediated further downstream. Screenz runs AI-led candidate interviews, scores applicants against role criteria, and follows up with employee check-ins after hire. The Candidate Screener, described as part of Nebula AI's system, runs a short voice screen and books a meeting with a recruiter only when a candidate passes. AIOS is listed as a YC W20/S21 company on Ashby, and its recruiting operation is described as "an AIOS system from Nebula AI," though the relationship between Nebula AI and the other platforms is not spelled out.

For candidates, the practical effect is that visibility depends on which platform they use. RoleIQ attaches an honest fit report to referrals and routes profiles to recruiters working specific roles. Wellfound offers access to dedicated recruiters. Jobfinder AI provides continuous refresh but no additional filtering. The platforms compete as much as they complement — each claims to cut through the noise of biased job descriptions and ATS filters, but the result is a candidate journey that branches rather than funnels.

The tension with AIOS's stated mission is subtle but real. The company's Ashby listing emphasizes building an AI operating system for consumer healthcare with near-zero marginal human time, yet the screening infrastructure it leans on is still being assembled across multiple vendors. Until those platforms consolidate or AIOS standardizes its process, candidates advance not by clearing a single bar but by satisfying whichever system happens to surface their profile first.

Implications for Frontier Biotech Talent Acquisition

AIOS's 18-role sprint sits inside a biotech labor market that has spent the last year shedding jobs faster than it added them. The contrast reads as a strategic bet rather than a market-following move. Between January 2023 and March 2025, life sciences layoffs accumulated across every major cluster — Massachusetts alone recorded more than 11,000 cuts in September 2025, with Moderna trimming 10 percent of its workforce, Sarepta Therapeutics cutting 36 percent, and Thermo Fisher closing 300 viral-vector roles. CBRE's April 2025 report put the unemployment rate for life, physical, and social scientists at 3.1 percent, nearly double the prior year, even as the broader economy held steady at 3.9 percent.

Against that backdrop, AIOS advertises compensation bands that look more like growth-stage tech than traditional biotech. The board data shows 12 salaried roles, with salary bands stretching from $91k to $400k and a median of $300k. The Head of Funnel Conversion (CRO) carries a $200k–$400k range plus up to 0.3 percent equity; the Software Engineer, Growth offers €60k–€120k hybrid in Kosovo with equity. These numbers sit comfortably alongside Series A/B fintech listings on the same board, not beside the wage premiums typical of legacy pharma. It signals that AIOS competes for product and growth talent first, and clinical expertise second — a reordering that reflects how GLP-1 companies now treat patient acquisition as a software problem.

That repositioning matters because it compresses two historically separate hiring funnels into one. AIOS lists Clinical Pharmacist (Independent Prescriber) alongside Head of Viral Social (UGC & Clippers), Product Manager - Engagement, and Media Buyer (Paid Search) in the same breath. The board data shows roles spanning remote U.S. engineering, hybrid Kosovo development, UK prescribing, and Lancashire warehouse operations — a geographic spread that mirrors the distributed playbook of digital-health startups rather than the campus-centric model of Genentech-era biotech.

The screening process itself reflects a second trend: the collapse of the traditional biotech resume filter. Over 75 percent of life science companies surveyed by Intuition Labs reported implementing some form of AI in the prior two years, and AIOS's multi-stage process — automated tools feeding into human interviews with explicit mission-alignment checks — reads as a prototype for what that integration looks like on the candidate side. Where legacy biotech still screens for tenure at known names, AIOS screens for demonstrated output in growth channels and clinical understanding. The difference is structural: a candidate who can point to a viral loop that converted 500,000 referrals carries more weight than one who spent five years at a branded pharma subsidiary.

That shift is forcing competitors to choose between two talent models. The first doubles down on the traditional biotech funnel: specialized roles, credential-based screening, and compensation anchored to regional wage premiums — North Carolina life science jobs still pay 84 percent above the state average, San Diego averages $120,700. The second, which AIOS occupies, treats GLP-1 adoption as a consumer-tech scale challenge and hires accordingly. Companies like Novo Nordisk and Eli Lilly have begun posting growth-marketing roles with equity packages that mirror AIOS's bands, suggesting the latter model is already bleeding into incumbents.

The countermove is coming from fractional talent networks. Pharmaceutical execs-turned-consultants now populate LinkedIn posts describing arrangements where a single clinical advisor splits time across three GLP-1 startups — a workaround for companies unwilling to match AIOS's salary bands but unable to hire slowly. CBRE noted in June 2025 that companies are "investing in specialized talent to drive pipeline acceleration and cost-efficient manufacturing," a phrase that could describe AIOS's engineering-heavy build or a contract research organization's staffing model depending on who's saying it.

What AIOS signals to competitors is not just how fast it can move, but how it defines the talent shortage. A 2022 survey found 96 percent of biopharma executives believed the talent gap would persist because the current pipeline doesn't fill it. AIOS's response is to stop waiting for the pipeline and start building a parallel one — recruiting engineers who can ship code, marketers who can write prescriptions, and designers who can navigate FDA-style compliance, all under one roof. If that model proves scalable, it won't just change how GLP-1 companies hire; it will redefine what counts as biotech talent in the first place.

Working in frontier tech? Zero G Talent tracks the openings: see every open AIOS role, browse frontier tech jobs, the companies hiring, and the people building the field.